Instead, they target hormone signalling systems that tell the body when it's full and slow down digestion
Mason et al., 2022
This GLP-1 Receptor Agonist for weight loss exclusion existed for Pennsylvania ACA Small Group & Individual (and Small Group Grand-mothered in Northeastern PA) already Weight loss medications, including GLP-1s FDA approved for weight loss , is automatically excluded from coverage beginning with December 1, 2024 plan renewal dates and upon renewals occurring thereafter for the following newly impacted PA segments: PA Fully Insured Large Group ( unless specifically meeting grandfathered status requirements ) PA Fully Insured Small Group Grand-mothered in Western PA and Central PA Coverage of GLP-1s FDA approved for diabetes will not be impacted, although some Authorizations or Medical Management may apply
Endoscopic bariatric therapy offers a less invasive option for patients reluctant to undergo surgery and includes various procedures such as space-occupying devices, restrictive procedures, and aspiration therapies [8]
Transaction Multiples and the LOE Discount When a drug with near-term LOE is acquired, the transaction multiple reflects the residual patent life
These are the largest weight reductions reported for any pharmacological agent in clinical trials